Ravulizumab in neuromyelitis optica spectrum disorder: first clinical experience in Chile. (PubMed, Front Immunol) - Oct 24, 2026 - "In this real-world Chilean cohort, ravulizumab was associated with complete relapse suppression over a median follow-up of 15 months and was well tolerated. These preliminary, uncontrolled observations are consistent with the relapse-prevention efficacy reported in pivotal trials and with regional consensus guidance on its use after rituximab failure, and they underscore the need to expand equitable access to complement-targeted therapies within the Chilean healthcare system."
Journal • Retrospective data • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Ocular Inflammation • Oncology • Ophthalmology • Optic Neuritis • Pain • Rare Diseases
|
|
César Romero; José Miguel Valdes; Lorna Galleguillos; Manuel Fruns; Tamara Santibañez
|